miR-503-5p induces doxorubicin resistance in triple-negative breast cancer.

Iris Garrido Cano,Anna Adam-Artigues,Ana Lameirinhas,Birlipta Pattanayak,Eduardo Tormo,Vera Miranda-Gonçalves,Catarina Macedo-Silva,Federico Rojo,Sandra Zazo,Juan Madoz-Gúrpide,Octavio Burgues,Cristina Hernando,Maite Martínez,Santi Moragón,Begoña Bermejo de las Heras,Ana Lluch,Carmen Jerónimo,Pilar Eroles,Juan Miguel Cejalvo

miR-503-5p induces doxorubicin resistance in triple-negative breast cancer.

2021

Iris Garrido Cano
Anna Adam-Artigues
Ana Lameirinhas
Birlipta Pattanayak
Eduardo Tormo
Vera Miranda-Gonçalves
Catarina Macedo-Silva
Federico Rojo
Sandra Zazo
Juan Madoz-Gúrpide
Octavio Burgues
Cristina Hernando
Maite Martínez
Santi Moragón
Begoña Bermejo de las Heras
Ana Lluch
Carmen Jerónimo
Pilar Eroles
Juan Miguel Cejalvo

1083Background: Triple-negative breast cancer (TNBC) is an aggressive breast cancer (BC) subtype comprising approximately 15% of BC. Conventional cytotoxic chemotherapies continue to be the mainsta...

Keywords:

Cancer research
Triple-negative breast cancer
Medicine
DOXORUBICIN RESISTANCE
Breast cancer
Cytotoxic T cell

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations